Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation

Annals of Family Medicine

Volumn 7, Issue 1, 2009, Pages 11-16

  Jimbo, Masahito ^a,f   Myers, Ronald E ^b   Meyer, Birgit ^c   Hyslop, Terry ^b   Cocroft, James ^b   Turner, Barbara J ^d   Weinberg, David S ^e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f NONE   (United States)

Author keywords

Colorectal neoplasm; FOBT; Follow up studies; Mass screening; Occult blood fecal

Indexed keywords

EID: 61449255273     PISSN: 15441709     EISSN: 15441717     Source Type: Journal    
DOI: 10.1370/afm.906     Document Type: Article

References (29)

1. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58(3):130-160.
2. US Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med. 2002;137(2):129-141.
3. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348(9040):1472-1477.
4. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467-1471.
5. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328(19):1365-1371.
6. Morris JB, Stellato TA, Guy BB, Gordon NH, Berger NA. A critical analysis of the largest reported mass fecal occult blood screening program in the United States. Am J Surg. 1991;161(1):101-105. [discussion 105-106].
7. Myers RE, Balshem AM, Wolf TA, Ross EA, Millner L. Screening for colorectal neoplasia: physicians' adherence to complete diagnostic evaluation. Am J Public Health. 1993;83(11):1620-1622.
8. Levin B, Hess K, Johnson C. Colorectal cancer screening in the community: adequacy of follow-up is related to physician specialty. Gastroenterology. 1996;110:A550.
9. Lurie JD, Welch HG. Diagnostic testing following fecal occult blood screening in the elderly. J Natl Cancer Inst. 1999;91(19):1641-1646.
10. Sharma VK, Vasudeva R, Howden CW. Colorectal cancer screening and surveillance practices by primary care physicians: results of a national survey. Am J Gastroenterol. 2000;95(6):1551-1556.
11. Shields HM, Weiner MS, Henry DR, et al. Factors that influence the decision to do an adequate evaluation of a patient with a positive stool for occult blood. Am J Gastroenterol. 2001;96(1):196-203.
12. Ko CW, Dominitz JA, Nguyen TD. Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am J Med. 2003;115(2):111-114.
13. Nadel MR, Shapiro JA, Klabunde CN, et al. A national survey of primary care physicians' methods for screening for occult blood. Ann Intern Med. 2005;142(2):86-94.
14. Etzioni DA, Yano EM, Rubenstein LV, et al. Measuring the quality of colorectal cancer screening: the importance of follow-up. Dis Colon Rectum. 2006;49(7):1002-1010.
15. Fisher DA, Jeffreys A, Coffman CJ, Fasanella K. Barriers to full colon evaluation for a positive fecal occult blood test. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1232-1235.
16. Garman KS, Jeffreys A, Coffman C, Fisher DA. Colorectal cancer screening, comorbidity, and follow-up in elderly patients. Am J Med Sci. 2006;332(4):159-163.
17. Myers RE, Turner B, Weinberg D, et al. Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. Prev Med. 2004;38(4):375-381.
18. Myers RE, Fishbein G, Hyslop T, et al. Measuring complete diagnostic evaluation in colorectal cancer screening. Cancer Detect Prev.2001;25(2): 174-182.
19. Myers RE, Turner B, Weinberg D, et al. Complete diagnostic evaluation in colorectal cancer screening: research design and baseline findings. Prev Med. 2001;33(4):249-260.
20. American College of Physicians. Clinical guideline: part I: suggested technique for fecal occult blood testing and interpretation in colorectal cancer screening. Ann Intern Med. 1997;126(10):808-810.
21. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology. 2006;130(6):1872-1885.
22. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003;124(2):544-560.
23. Macrae FA, St John DJ, Caligiore P, Taylor LS, Legge JW. Optimal dietary conditions for hemoccult testing. Gastroenterology. 1982;82(5 Pt 1):899-903.
24. Pye G, Ballantyne KC, Armitage NC, Hardcastle JD. Influence of non-steroidal anti-inflammatory drugs on the outcome of faecal occult blood tests in screening for colorectal cancer. Br Med J (Clin Res Ed). 1987;294(6586):1510-1511.
25. Greenberg PD, Cello JP, Rockey DC. Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease. Am J Med. 1996;100(6):598-604.
26. Baig N, Myers RE, Turner BJ, et al. Physician-reported reasons for limited follow-up of patients with a positive fecal occult blood test screening result. Am J Gastroenterol. 2003;98(9):2078-2081.
27. Seef LC, King J, Pollack A, Williams KN. Increased use of colorectal cancer tests-United States, 2002 and 2004. MMWR Morb Mortal Wkly Rep. 2006;55(11):308-311.
28. Seeff LC, Manninen DL, Dong FB, et al. Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States? Gastroenterology. 2004;127(6):1661 -1669.
29. National Cancer Institute. The NCI Strategic Plan For Leading the Nation to Eliminate the Suffering and Death Due to Cancer. Bethesda, MD: National Cancer Institute; 2006.